US › Healthcare

Crescent Biopharma, Inc. (CBIO)

US · Healthcare · Biotechnology

$16.38+10.15%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-24.8M
Profit YoY
-14.0%
EPS
$-0.74
EPS estimate
$-0.78

EPS came in at -0.74 against a street estimate of -0.78 — a beat of 5.1%.

Key statistics

Market cap
$537.5M
Forward P/E
0.0
P/B
3.37
Book value
$4.77
EPS (TTM)
$-0.14
52-week high
$27.41
52-week low
$8.72
50-day MA
$17.47
200-day MA
$14.88

Analyst view

with an average price target of $30.60.

Shareholding

Insiders
0.42%
Institutions
74.55%

Largest institutional holders

FundStake
FMR Inc11.59%
Bvf Inc7.71%
Fairmount Funds Management LLC7.70%
VR Adviser, LLC5.98%
FCPM III SERVICES BV4.70%
Balyasny Asset Management LLC4.23%
Vestal Point Capital LP4.21%
Opaleye Management Inc3.68%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Crescent Biopharma, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.